ANZAC: A Randomised Neoadjuvant Biomarker Study Investigating the Anti-Tumour Activity of the Addition of Zoledronic Acid to Chemotherapy in Breast Cancer

被引：1
|
作者：
Winter, M. C.
Syddall, S. P.
Cross, S. S.
Evans, A.
Ingram, C. E.
Jolley, I. J.
Hatton, M. Q.
Mori, S.
Holen, I.
Coleman, R. E.
机构：
[1] Univ Sheffield, Sheffield S10 2TN, S Yorkshire, England
[2] Sheffield Teaching Hosp NHS Fdn Trust, Sheffield, S Yorkshire, England
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-P1-11-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-11-01
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Catumaxomab Induces Efficient Anti-tumour Activity in Vitro With Immune Cells From Ovarian Cancer Patients After Chemotherapy Treatment
    Braicu, I.
    Atz, J.
    Dettmar, K.
    Martinius, H.
    Spannagl, R.
    Seimetz, D.
    Lindhofer, H.
    Chekerov, R.
    Pietzner, K.
    Sehouli, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S529 - S529
  • [42] Anti-tumour effects of zoledronic acid and somatostatin analogues in murine androgen-independent neuroendocrine carcinoma as hormone-refractory prostate cancer model
    Hashimoto, K.
    Masumori, N.
    Tanaka, T.
    Uchida, K.
    Tsukamoto, T.
    [J]. EJC SUPPLEMENTS, 2010, 8 (05): : 128 - 128
  • [43] The value of tumour infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a study in a hospital complex
    Cordoba, A.
    Ruiz de Azua, Y.
    Arean, C.
    Aguiar, B.
    Nova, L.
    Labiano, T.
    Ulazia, A.
    Guerrero, D.
    [J]. VIRCHOWS ARCHIV, 2018, 473 : S56 - S56
  • [44] A randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer
    Hasegawa, Y.
    Kohno, N.
    Horiguchi, J.
    Miura, D.
    Ishikawa, T.
    Hayashi, M.
    Takao, S.
    Kim, S. J.
    Tanino, H.
    Miyashita, M.
    Konishi, M.
    Shigeoka, Y.
    Yamagami, K.
    Akazawa, K.
    [J]. CANCER RESEARCH, 2012, 72
  • [45] Randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer
    Kohno, Norio
    Hasegawa, Yoshie
    Horiguchi, Jun
    Ishikawa, Takashi
    Miura, Daishu
    Hayashi, Mitsuhiro
    Takao, Shintaro
    Kim, Seung Jin
    Tanino, Hirokazu
    Akazawa, Kohei
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [46] A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer
    Rita D Brandão
    Jürgen Veeck
    Koen K Van de Vijver
    Patrick Lindsey
    Bart de Vries
    Catharina HMJ van Elssen
    Marinus J Blok
    Kristien Keymeulen
    Torik Ayoubi
    Hubert JM Smeets
    Vivianne C Tjan-Heijnen
    Pierre S Hupperets
    [J]. Breast Cancer Research, 15
  • [47] A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer
    Brandao, Rita D.
    Veeck, Juergen
    Van de Vijver, Koen K.
    Lindsey, Patrick
    de Vries, Bart
    van Elssen, Catharina H. M. J.
    Blok, Marinus J.
    Keymeulen, Kristien
    Ayoubi, Torik
    Smeets, Hubert J. M.
    Tjan-Heijnen, Vivianne C.
    Hupperets, Pierre S.
    [J]. BREAST CANCER RESEARCH, 2013, 15 (02)
  • [48] Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS 126 in models of triple-negative breast cancer
    Jens C. Hahne
    Heike Schmidt
    Susanne R. Meyer
    Jörg B. Engel
    Johannes Dietl
    Arnd Honig
    [J]. Journal of Cancer Research and Clinical Oncology, 2013, 139 : 905 - 914
  • [49] Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS 126 in models of triple-negative breast cancer
    Hahne, Jens C.
    Schmidt, Heike
    Meyer, Susanne R.
    Engel, Joerg B.
    Dietl, Johannes
    Honig, Arnd
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (06) : 905 - 914
  • [50] The addition of zoledronic acid to combination chemotherapy decreases circulating serum levels of vascular endothelial growth factor (VEGF) in early breast cancer
    Winter, M. C.
    Evans, A.
    Holen, I.
    Coleman, R. E.
    [J]. BONE, 2011, 48 (01) : S30 - S31
12345